NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer

Cancer Research

Volumn 58, Issue 22, 1998, Pages 5123-5129

  Christianson, Tracy A ^a   Doherty, Joni K ^b   Lin, Yuzhong J ^a,c   Ramsey, Elizabeth E ^b   Holmes, Ron ^b   Keenan, Edward J ^b   Clinton, Gail M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Cascade Biologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; ONCOGENE NEU; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL STRAIN 3T3; CHEMISTRY; DRUG ANTAGONISM; FEMALE; METABOLISM; MOLECULAR WEIGHT; MOUSE; PATHOLOGY; PHOSPHORYLATION;

DIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXAMIC ACID; METALLOPROTEINASE; N ((2 (HYDROXYAMINOCARBONYL)METHYL) 4 METHYLPENTANOYL) 3 (2' NAPHTHYL)ALANYLALANINE, 2 AMINOETHYLAMIDE; N-((2-(HYDROXYAMINOCARBONYL)METHYL)-4-METHYLPENTANOYL)-3-(2'-NAPHTHYL)ALANYLALANINE, 2-AMINOETHYLAMIDE; PROTEIN TYROSINE KINASE; SCLEROPROTEIN; TUMOR PROTEIN;

3T3 CELLS; ANIMALS; BREAST NEOPLASMS; DIPEPTIDES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; MICE; MOLECULAR WEIGHT; NEOPLASM PROTEINS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0032532950     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
2. Kern, J. A., Schwardz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L., and Robinson, R. A. P185HER-2/neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res., 50: 5184-5191, 1990.
3. Cohen, J. A., Weiner, D. B., More, K. F., Kodai, Y., Williams, W. V., Maguire, H. C. J., LiVolsi, V. A., and Greene, M. I. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene, 4: 81-88, 1989.
4. Arai, Y., Yoshiki, T., and Yoshida, O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate, 30: 195-201, 1997.
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
6. Singleton, T. P., and Strickler, J. G. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu., 27: 165-198, 1992.
7. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
8. Press, M. F., Jones, L. A., Godolphin, W., Edwards, C. L., and Slamon, D. J. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog. Clin. Biol. Res., 354: 209-221, 1990.
9. Hynes, N. E., and Sterne, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
10. Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.
11. Lin, Y. J., and Clinton, G. M. A soluble protein related to the HER-2/neu proto-oncogene product is released from human breast carcinoma cells. Oncogene, 6: 639-643, 1991.
12. Zabrecky, J. R., Lam, T., and McKenzie, S. J. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem., 266: 1716-1720, 1991.
13. Pupa, S. M., Crepaldi, L., Gandino, S., Longati, P., and Comoglio, P. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.
14. Scott, G. K., Robles, R., Park, J. W., Montgomery, P. A., Danie, I J., Holmes, W. E., Lee, J., Keller, G. A., Li, W. L., Fendly, B. M., Wood, W. I., Shepard, H. M., and Benz, C. C. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell. Biol., 13: 2247-2257, 1993.
15. Leitzel, K., Teramoto, Y., Sampson, E., Maurceri, J., Langton, B. C., Demers, L., Podczaski, E., Harver, H., Shambaugh, S., Volas, G., Weaver, S., and Lipton, A. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J. Clin. Oncol., 10: 1436-1443, 1992.
16. Maden, H., Marx, D., Schauer, A., and Kuhn, W. Prognostic significance of p105 (c-erbB-2 HER-2/neu) serum levels in patients with ovarian cancer. Anticancer Res., 17: 757-760, 1997.
17. Myers, R. B., Brown, D., Oelschlager, D. K., Waterbor, J. W., Marshall, M. E., Srivastava, S., Stockard, C. R., Urban, D. A., and Grizzle, W. E. Elevated serum levels of p105 (ErbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int. J. Cancer, 69: 398-402, 1996.
18. Brandt-Rauf, P. W. The c-erb transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat. Res., 333: 203-208, 1995.
19. Molina, R., Zanon, J. J., Filella, X., Farrus, B., Munoz, M., Latre, M. L., Pahisa, J., Velasco, M., Fernandez, P., Estape, J., and Bassesta, A. M. Utility of c-erB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br. J. Cancer, 4: 1126-1131, 1996.
20. Brodowicz, K. M., Zeillinger, R., Wiltschke, C., Scholten, C., Seifert, M., Kubista, E., and Zielinski, C. C. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology, 54: 475-481, 1997.
21. Kandl, H., Seymour, L., and Bezwoda, W. R. Soluble c-erbB-2 fragment in serum correlates with disease state and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer, 70: 739-742, 1994.
22. Fehm, T., Maimonis, P., Katalinic, A., and Jager, W. H. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology, 55: 33-38, 1998.
23. Mansour, O. A., Zekri, A. R., Harvery, J., Teramoto, Y., and Elahmady, O. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res., 17: 3101-3105, 1997.
24. Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V. M., Volas, G., Grossberg, H., Harvey, H., Demers, L., and Lipton, A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13: 1129-1135, 1995.
25. Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S., and Hayes, D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 2518-2525, 1997.
26. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T. T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
27. Brodowicz, T., Wiltschke, C., Budinsky, A. C., Krainer, M., Steger, G. G., and Zielinski, C. C. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int. J. Cancer., 73: 875-879, 1997.
28. Downing, J. R., Roussel, M. F., and Sherr, C. J. Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol. Cell. Biol., 9: 2890-2896, 1989.
29. Cabrera, N., Diaz-Rodriguez, E., Martin-Zanca, D., and Pandiella, A. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J. Cell. Biol., 132: 427-436, 1996.
30. O'Bryan, J. P., Fridell, Y. W., Koski, R., Varnum, B., and Liu, E. T. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J. Biol. Chem., 270: 551-557, 1995.
31. Vecchi, M., Baulida, J., and Carpenter, G. Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J. Biol. Chem., 271: 18989-18995, 1996.
32. Vecchi, M., and Carpenter, G. Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique sequential mechanism. J. Cell Biol., 139: 995-1003, 1997.
33. DiFiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. ErbB-2 is a potent oncogene when overexpressed in NIH3T3 cells. Science (Washington DC), 237: 178-182, 1987.
34. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor p185HER-2 causes transformation and tumorigenesis of NIH3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
35. Segatto, O., King, R., Pierce, J. H., DiFiore, P. P., and Aaronson, S. A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol., 8: 5570-5574, 1988.
36. Bargmann, C. I., and Weinberg, R. A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J., 7: 2043-2052, 1988.
37. Rodrigues, G. A., and Park, M. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev., 4: 15-24, 1994.
38. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L., and Wong, A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55: 5536-5539, 1995.
39. Moscatello, D. K., Montgomery, R. B., Sundareshan, P., McDanel, H., Wong, M. Y., and Wong, A. J. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene, 13: 85-96, 1996.
40. Huang, H-J., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X-D., Huang, C-M., Gill, G. G., Wiley, H. S., and Cavenee, W. K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem., 272: 2927-2935, 1997.
41. Lin, Y. J., Li, S., and Clinton, G. M. Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2/neu in the breast carcinoma cell line, BT474. Mol. Cell. Endocrinol., 69: 111-119, 1990.
42. McKenzie, S. J., Marks, P. J., Lam, T., Morgan, J., Panicali, D. L., Trimpe, K. L., and Carney, W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4: 543-548, 1989.
43. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605-610, 1987.
44. Ehlers, M. R., and Riordan, J. F. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry, 30: 10065-10074, 1991.
45. Hooper, N. M., Karran, E. H., and Turner, A. J. Membrane protein secretases. Biochem. J., 321: 265-279, 1997.
46. McGeehan, G. M., Becherer, J. D., Bast, R. C., Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., and McElroy, A. B. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature (Lond.), 370: 558-561, 1994.
47. Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torrance, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S. R., Petersen, M., Gerhart, M., Kozlosky, C. J., March, C. J., and Black, R. A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (Lond.), 370: 218-220, 1994.
48. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massague, J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem., 271: 11376-11382, 1996.
49. McGuire, W. L., and Clark, G. M. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N. Engl. J. Med., 326: 1756-1761, 1992.
50. Seedorf, K., Shearman, M., and Ullrich, A. Rapid and long term effects of protein kinase C on receptor tyrosine kinase phosphorylation and degradation. J. Biol. Chem., 270: 18953-18960, 1995.
51. Marshall, S. Kinetics of insulin receptor internalization and recycling in adipocytes. J. Biol. Chem., 260: 4136-4144, 1985.
52. Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., and McGuire, W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol., 7: 1120-1128, 1989.
53. Carlomagno, C., Perrone, F., Gallo, C., DeLaurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., and De Placido, S. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol., 14: 2702-2708, 1996.